pdsbiotech.com Open in urlscan Pro
69.16.221.82  Public Scan

Form analysis
1 forms found in the DOM

GET /component/finder/search

<form id="mod-finder-searchform129" action="/component/finder/search" method="get" class="form-search" role="search">
  <label for="mod-finder-searchword129" class="element-invisible finder">Search</label><input type="text" name="q" id="mod-finder-searchword129" class="search-query input-medium" size="25" value="" placeholder="Search ...">
  <input type="hidden" name="Itemid" value="186">
</form>

Text Content

Skip to main content
 * About
   *  * Back
      * Leadership Team
      * Board of Directors
      * Scientific Advisors
 * Platform Technologies
   *  * Back
      * Versamune®
        *  * Back
           * About Versamune®
           * Introduction to Immunotherapies
      * Infectimune™
        *  * Back
           * About Infectimune™
           * Transformative Vaccines
      * Partnerships
      * Publications
 * Pipeline
   *  * Back
      * Overview
      * Oncology
        *  * Back
           * PDS0101
           * PDS0102
           * PDS0103
           * PDS0104
      * Infectious Disease
        *  * Back
           * PDS0201
           * PDS0202
           * PDS0203
      * Clinical Trials
        *  * Back
           * Expanded Access
 * Investors and Media
   *  * Back
      * News Center
        *  * Back
           * Press Releases
             *  * Back
                * News 2022
                * News 2021
                * News 2020
                * News 2019
           * Events
             *  * Back
                * Upcoming
                * Archive
           * Media Resources
      * Investor Resources
        *  * Back
           * Corporate Presentations
           * FAQs
           * Investor Email Alerts
      * Stock Info
        *  * Back
           * Stock Quote and Chart
           * Historical Price Lookup
           * Analyst Coverage
      * SEC Filings
      * Corporate Governance
        *  * Back
           * Governance Documents
           * Committee Composition
 * Contact
   *  * Back
      * Media
      * Investors
      * Business Development and Licensing
 * 
 * 
 * Sign Up


Search
 

  

   VERSATILE-002 – Preliminary Phase 2 Results in Recurrent or Metastatic Head
and Neck Cancer: 76.5% of patients had either disease stabilization or tumor
shrinkage; 89% of patients alive at median 9 months suggesting survival benefit
Presentation NCI-led Triple Combination – Preliminary Phase 2 Results in
Advanced, Metastatic HPV-Positive Cancers: 77% of patients who had failed all
prior treatments including immunotherapy remained alive at 1-year; 75% of
patients not exposed to immunotherapy were alive at median follow up of 17
months  Presentation





TRANSFORMING CANCER TREATMENT
WITH MOLECULARLY TARGETED T-CELL IMMUNOTHERAPY

Powerful
Versamune®
Platform

Our Versamune® platform trains the immune system to unleash a powerful targeted
T-cell attack and could dramatically improve treatment and patient outcomes
across the cancer spectrum.

LEARN MORE

Novel
Combination
Products

Our robust pipeline of promising cancer treatments is aimed at improving current
cancer treatments by combining our products with FDA-approved standard of care
and with other promising, clinical-stage immunotherapeutic agents.

LEARN MORE

World
Renowned
Partners

We have partnered with some of the world’s leading research institutions and
pharmaceutical companies to develop more effective Versamune®-based cancer
therapies and infectious disease vaccines to save lives.

LEARN MORE

Featured Publications

Peer Reviewed Publications

--------------------------------------------------------------------------------

--------------------------------------------------------------------------------

Company Presentations

--------------------------------------------------------------------------------

Versamune®: A New Generation
of Cancer Immunotherapies

--------------------------------------------------------------------------------

PDS0101: Interim Data for the Treatment of HPV-Associated Cancers

--------------------------------------------------------------------------------

2021 Oncology R&D Day


LATEST NEWS

 * Oct 27, 2022
   
   PDS Biotech Provides Highlights from Head and Neck...
   
   
   
   Read More
   

 * Oct 25, 2022
   
   PDS Biotech Chief Medical Officer Dr. Lauren V. Wo...
   
   
   
   Read More
   

 * Oct 19, 2022
   
   PDS Biotech to Present at the LD Micro Main Event ...
   
   
   
   Read More
   


Versamune® Mechanism of Action Video

About Us

PDS Biotech is a clinical stage biopharmaceutical company with a growing
pipeline of cancer immunotherapies and infectious disease vaccines. Our team is
committed to developing first-in-class T-cell activating immunotherapies based
on the Versamune® platform to fight against cancer. We are also developing novel
preventive vaccines based on the Infectimune™ platform to provide more rapid and
longer-lasting protection against infectious agents.

Corporate presentation >>

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up



© 2022 PDS Biotechnology. All Rights Reserved

Site & CMS By Sandman Media Inc